Tranexamic acid

• CAS: 1197-18-8
• Catalog Number: ALC-FP-1197188
• Category: Featured Products
• Solubility: Freely soluble in water, and practicallyinsoluble in ethanol (99.5%)
• Appearance: White or almost white, crystalline power
• As: ≤ 2ppm
• Ash Content: ≤ 0.1%
• Assay: 98-101%
• Cl: ≤ 140ppm
• Heavy Metal: ≤ 10ppm
• Drying Loss: ≤ 0.5%
• pH: 7.0-8.0
• Related Substances: Impurity A ≤0.1%; Impurity B ≤0.2%; Any other impurity ≤0.1%; All other impurity ≤0.2%
• Sample Lot No.: 240629

Case Study

Tranexamic Acid for Reducing Surgical Blood Loss in Burn Patients

Hesamirostami M, et al. Burns, 2025, 107682.

A randomized double-blind clinical trial evaluated the efficacy of tranexamic acid (TXA) in minimizing intraoperative bleeding during surgical excision in burn patients. Sixty adult patients with 20-50% total body surface area burns of second and third degree were enrolled and randomly assigned to receive either TXA or 0.9% sodium chloride (placebo) as wound surface irrigation before closure. Both groups were comparable in demographics (p > 0.05). TXA-treated wounds demonstrated significantly lower intraoperative blood loss (p < 0.05) and a 65% reduction in postoperative infection risk compared to placebo. The need for blood products was also lower in the TXA group, with an average of 2.64 fewer transfused units. Notably, hemoglobin and hematocrit levels showed no significant differences between groups. These findings highlight the experimental application of TXA-soaked dressings as an effective perioperative hemostatic intervention.

Tranexamic Acid in Hyaluronic Acid/Collagen Membranes for Hemostatic and Wound Healing Applications

Alnawwar WH, et al. Colloids and Surfaces B: Biointerfaces, 2025, 252, 114647.

A binary hyaluronic acid/collagen (HA/COL) membrane was engineered via lyophilization, incorporating tranexamic acid (TRAX) and/or vitamin K to assess their hemostatic and wound healing potential. HA and COL (3 % each) were dissolved in deionized water, magnetically stirred for 2 h, and cast into molds before freezing (-20 °C, 24 h) and drying (-30 °C, 48 h) to yield porous membranes. Four formulations were fabricated: HA/COL, HA/COL/TRAX, HA/COL/Vit K, and HA/COL/TRAX/Vit K. Experimental evaluations included clotting time, coagulation factors (PT, PTT, INR), cytotoxicity (IC50 determination), and antimicrobial assays against Gram-positive/negative bacteria, yeast, and fungi. TRAX-loaded membranes enhanced clotting efficacy but showed higher cytotoxicity, whereas Vit K-loaded constructs promoted rapid coagulation with reduced toxicity. Antibacterial activity was attributed to HA. These findings highlight the experimental value of TRAX integration within bioengineered HA/COL scaffolds for hemostatic applications.